These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 28582730)
1. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems. Shin D; Kim EH; Lee J; Roh JL Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730 [TBL] [Abstract][Full Text] [Related]
2. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Roh JL; Kim EH; Jang H; Shin D Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440 [TBL] [Abstract][Full Text] [Related]
3. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Shin D; Kim EH; Lee J; Roh JL Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884 [TBL] [Abstract][Full Text] [Related]
4. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494 [TBL] [Abstract][Full Text] [Related]
5. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer. Kim EH; Jang H; Shin D; Baek SH; Roh JL Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755 [TBL] [Abstract][Full Text] [Related]
6. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Roh JL; Kim EH; Jang HJ; Park JY; Shin D Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897 [TBL] [Abstract][Full Text] [Related]
7. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer. Roh JL; Jang H; Kim EH; Shin D Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046 [TBL] [Abstract][Full Text] [Related]
8. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway. Kim EH; Baek S; Shin D; Lee J; Roh JL Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786 [TBL] [Abstract][Full Text] [Related]
9. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition. Kim EH; Jang H; Roh JL Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943 [TBL] [Abstract][Full Text] [Related]
10. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Roh JL; Park JY; Kim EH; Jang HJ; Kwon M Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904 [TBL] [Abstract][Full Text] [Related]
11. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer. Roh JL; Park JY; Kim EH Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507 [TBL] [Abstract][Full Text] [Related]
12. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. Roh JL; Kim EH; Jang H; Shin D Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599 [TBL] [Abstract][Full Text] [Related]
13. Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance. Bu Y; Cai G; Shen Y; Huang C; Zeng X; Cao Y; Cai C; Wang Y; Huang D; Liao DF; Cao D Cancer Lett; 2016 Dec; 383(2):261-271. PubMed ID: 27721021 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin. Roh JL; Kim EH; Park JY; Kim JW Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766 [TBL] [Abstract][Full Text] [Related]
15. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Kim EH; Shin D; Lee J; Jung AR; Roh JL Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961 [TBL] [Abstract][Full Text] [Related]
16. Targeting acid ceramidase sensitises head and neck cancer to cisplatin. Roh JL; Park JY; Kim EH; Jang HJ Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835 [TBL] [Abstract][Full Text] [Related]
17. Isodeoxyelephantopin induces protective autophagy in lung cancer cells via Nrf2-p62-keap1 feedback loop. Wang Y; Zhang J; Huang ZH; Huang XH; Zheng WB; Yin XF; Li YL; Li B; He QY Cell Death Dis; 2017 Jun; 8(6):e2876. PubMed ID: 28617433 [TBL] [Abstract][Full Text] [Related]
18. p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway. Liao W; Wang Z; Fu Z; Ma H; Jiang M; Xu A; Zhang W Free Radic Res; 2019 Jul; 53(7):800-814. PubMed ID: 31223046 [TBL] [Abstract][Full Text] [Related]
19. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling. Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222 [TBL] [Abstract][Full Text] [Related]
20. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Bao LJ; Jaramillo MC; Zhang ZB; Zheng YX; Yao M; Zhang DD; Yi XF Int J Clin Exp Pathol; 2014; 7(4):1502-13. PubMed ID: 24817946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]